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It has been suggested that the metabolic enzyme indoleamine 2,3-dioxygenase (IDO)
is a biological mediator of inflammation related to the psychopathology of depression,
with a Kynurenine (KYN) increase in the Tryptophan (TRP) metabolic pathway, resulting
in reduced Serotonin. In this study, we examined KYN, TRP, and the ratio of KYN to TRP
concentrations × 103 (KT Ratio) in serum and cerebrospinal fluid (CSF) in (a) a group of
depressed patients and (b) a control group of patients referred to a neurologic outpatient
clinic for whom no specific diagnosis could be established. The KT Ratio is considered
an index that represents IDO. The participants were examined with the Beck Depression
Inventory II (BDI-II), the Montgomery Aasberg Depression Rating Scale (MADRS), and a
neuropsychological test battery. We found no significant differences between the two
study groups with respect to TRP, KYN, or KT Ratio in serum or CSF. Differences
in neuropsychological performance between the two patient groups could be seen in
the following tests: Animal Fluency, Digit Symbol, the DKEFS Color-Interference Test
(Naming Part), Trail Making Test A and B, and the Grooved Pegboard Non-dominant
Hand. KYN in serum correlated highly with KYN in CSF. KYN in serum correlated
significantly with both age and gender. When analyzing males and females separately,
we found that women had a lower level of TRP in both serum (Mann–Whitney U-test:
TRP in Serum; p = 0.001) and CSF (Mann–Whitney U-test: TRP in CSF; p = 0.003).
Women had a lower level of KYN in serum (p = 0.029) than men did. Age was positively
associated with KYN. KYN in CSF correlated only with age, however; there were no
gender differences. No significant relationship was seen between BDI-II and MADRS on
the one hand, and KYN and TRP on the other. KYN in CSF as the KT Ratio in both serum
and CSF was associated with neuropsychological performance. Thus, we suggest that
KYN and KT Ratio are related more strongly to neuropsychological performance than to
affective symptoms in depression.
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INTRODUCTION
Depression is the world’s most widespread mental disorder,
affecting over 350 million individuals (WHO, 2012). The
mechanisms thought to be associated with depression are (a)
signaling through neurotransmitters and (b) the axis of the
hypothalamus, pituitary and adrenal cortex, with (c) a more
recent focus on inflammation. These pathways, interacting with
each other, provide a biological basis for the development of
depression, and elevation of proinflammatory cytokines and
other signs of inflammation are frequently seen (Hestad et al.,
2003; Young et al., 2014; Poon et al., 2015). Examining gene
expression in major depression showed a significantly different
regulation of inflammatory/immune pathways than exhibited by
healthy controls (Jansen et al., 2015). And finally, in patients
who received pharmacological treatment with cytokines or
other immune modifiers, about 1/3 developed severe depression
(Dantzer et al., 1999; Capuron et al., 2002a,b,c). Yet, several other
patient groups that may be at least partly affected by psychological
factors—fatigue, myalgic encephalopathy, and schizophrenia, for
example—have also shown a rise in pro-inflammatory cytokines.
Low-grade inflammation seems to be a specific biomarker related
to depression, however. To examine this possibility, it would be
of interest to examine a similar patient control group with many
of the same symptoms, but with no signs of overt depression. We
did discuss the addition of a control group of healthy individuals,
but did not seriously consider it, given the requirement of a spinal
tap and the possible side effects it represents.
It has been suggested that the metabolic enzyme indoleamine
2,3-dioxygenase (IDO) is a biological mediator of inflammation
related to depressive disorders, as seen in animal models and
after drug therapy in humans with interferon-α (O’Connor et al.,
2009a,b; Raison et al., 2010). The effects on depression are via
IDO and Tryptophan-2,3-dioxygenase (TDO), with an increase
in Kynurenine (KYN) in the Tryptophan (TRP) metabolic
pathway, resulting in a reduced amount of Serotonin. Many
proinflammatory cytokines, such as IL-1, IL-2, IL-6, and IFN-γ
can induce IDO and TDO. TRP is the substrate for IDO and
TDO, and the metabolized product is KYN (Guillemin et al.,
2001). With inflammation, and as levels of IDO and TDO
increase, an increase in TRP will be used by IDO and TDO
in the KYN production. The result will be reduced TRP as
the basis for Serotonin production. As IDO and TDO increase,
there will be less production of Serotonin, which is associated
with depression (Hayaishi, 1996; Stone and Darlington, 2002;
Wirleitner et al., 2003; Schiepers et al., 2005). It has been shown
that the serum KYN-to-TRP Ratio (KYN/TRP × 103) KT Ratio
is a reliable indication of IDO (Schrocksnadel et al., 2006; Raison
et al., 2010). Because depression is linked to such monoamines
as Serotonin and Noradrenaline, there may be less regulation
in neurotransmission related to these neurotransmitters in
depression, with increased production of KYN (Schildkraut,
1965; Ressler and Nemeroff, 1999, 2000; Dursun et al., 2001;
Bonaccorso et al., 2002; Capuron et al., 2002c, 2003; Castanon
et al., 2002; Wichers and Maes, 2004; Muller and Schwarz, 2006).
In addition, IDO and TDO may activate depression through the
metabolite 3-hydroxy-kynerunine (3OH-KYN) and quinolinic
acid (QUIN) (Heyes et al., 1996; Guillemin et al., 2005).
3OH-KYN and QUIN are probably involved in a number of
neurodegenerative disorders, like Parkinson’s Disease and HIV-
dementia (Heyes et al., 1992; Stone, 2001; Wichers and Maes,
2004). Both 3OH-KYN and QUIN are neurotoxic, and it has
been proposed that QUIN can create atrophy of the hippocampus
and a reduction of corticosteroid receptors (Bremner et al., 2000;
Wichers and Maes, 2004).
Although several studies have examined plasma or serum
levels of inflammatory markers in psychopathology of depressive
disorders, data on Tryptophan, Kynurenine, Indoleamine 2,3-
dioxygenase in both serum and cerebrospinal fluid (CSF)
have rarely been studied. A PubMed search with the words
Tryptophan, Kynurenine, serum, CSF resulted in 21 studies, none
of which were related to depression. We wanted to rectify this
omission by examining these variables in a depressive group and
a control group of patients with no depression. In addition, we
asked: ‘How are serum and CSF levels connected?’
We hypothesized that patients with a diagnosis of depression
would present with a specific and different serum and CSF,
KYN, and TRP profile than would patients with no depression.
In particular, we expected to find higher levels of KYN and
KT Ratio in both serum and CSF among depressed patients
than among non-depressed patients. We therefore examined two
patient groups: one with depression and one without. The non-
depressed group, which served as a control group, was referred to
a neurological clinic because of diffuse (neurological) symptoms
such as fatigue, but no diagnosis could be established. Because a
recent study has demonstrated that IDO is related to depressive
symptoms more strongly in women than in men (Elovainio et al.,
2012), we analyzed TRP, KYN, and KT Ratio separately for males
and females.
Cognitive dysfunction is common in depression (Veiel, 1997;
Gualtieri et al., 2006; Farup and Hestad, 2015). It is not
known, however, whether it is part of the development of
affective symptoms in depression or if two separate developments
and biological pathways are involved. We therefore posed two
research questions.
(1) Does the concentration of TRP, KYN, and KT Ratio in
serum and CSF differ between patients with depression
and a similar patient group without depression? And as
a secondary aim, do patients with depression differ in
cognitive performance compared to patient group with no
depression?
(2) Are TRP and/or KYN and KT Ratio concentrations in
serum and CSF associated with affective symptoms and/or
cognitive performance?
MATERIALS AND METHODS
Patients and Controls
A group of 49 depressed patients were recruited from inpatient
wards and outpatient clinics of the Mental Health Unit at
Innlandet Hospital Trust, Norway. They were all over 18 years
of age and were diagnosed with depression using (a) the
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International Statistical Classification of Diseases and Related
Health Problems, 10th revision [ICD-10], F32–34 spectra; and (b)
DSM-IVTR, mood disorders. For participants in the depression
group, it was decided that brain imaging should be conducted if
there were any indication or suspicion of cerebral disorder. None
of the depressed patients showed any indication or suspicion of
such a disorder, so they were not examined with brain imaging.
Thirteen of the 49 depressive patients were using a
combination of anti-depressive and antipsychotic medication;
22 were medicated with anti-depressives only and 3 with only
antipsychotic medication.
The control group comprised 31 patients over 18 years
of age with neurological symptoms who were referred to
the Department of Neurology at the same hospital for a
thorough investigation. The inclusion criteria were no disease
and no neurological sign of disease. None of the patients had
neurological signs of disease; and none of their laboratory tests
indicated cerebral disorder. Clinically, they had many similar
symptoms seen in depressed patients, including tiredness, fatigue,
lack of initiative, and the feeling that the body is not functioning.
They had no overt signs of depression, however: mood changes
or emotional state. Other than depression, the most common
symptom was fatigue, as reported by 45 of the depressed patients
and 25 of the controls. Nineteen of the control patients had a
neuropsychological assessment and were included in the study.
Of these 19 controls, 14 reported fatigue. Lack of funding
prevented our giving 12 patients from the control group a
neuropsychological examination when they were recruited.
All patients were recruited consecutively from either the
psychiatric or neurological ward after the psychiatrists or
neurologists, who were informed about the study, determined
that the patients met the criteria for inclusion in the study.
Examinations and Assessments
A medical history was recorded, a routine clinical examination
performed, and hematological and biochemical screening tests
conducted on all participants. Peripheral blood was collected,
allowed to clot for 30 min before 10 min of centrifugation at
2000 g. CSF samples were obtained by a trained neurologist
and centrifuged within 30 min at 2000 g for 10 min. Serum
and CSF was aliquoted and stored at −70◦C until analyses were
performed. All blood samples were taken between 08.30 and
10.00. The spinal tap was done before 12.00 noon, except for two
depressed patients for whom the procedure was performed closer
to 13.00. The patients were not required to fast before blood or
CSF sampling.
A neurologist conducted a detailed examination of the
patients, including a routine examination of CSF, in the
Department of Neurology.
TRP and KYN levels in serum and CSF were determined by
high-performance liquid chromatography (Widner et al., 1997).
In brief, an aliquot of 200 µL serum was precipitated with
125 µl 25% (w/v) trichloroacetic acid, mixed, and centrifuged.
For separation, reversed-phase Kinetex columns (2.6 µ C18
100A) from Phenomenex (Torrance, CA, United States) were
used. KYN was detected with an ultraviolet absorption detector,
and TRP was detected using a fluorescence detector. Instrumental
analysis was performed on Agilent Infinity 1290 (Agilent
Technologies, Santa Clara, CA, United States). The KT Ratio was
calculated and used as a measure of tryptophan degradation and
as IDO indicator.
All patients were examined independently with two
depression scales. (a) Montgomery Aasberg Depression Rating
Scale (MADRS) (Montgomery and Asberg, 1979) yielded four
categories: no depression 0–6, mild depression 7–19, moderate
depression 20–34, and severe depression > 34. (b) Beck
Depression Inventory II (BDI-II) (Beck et al., 1996; Steer et al.,
1997, 1999) also yielded four categories: minimal depression
0–13, mild depression 14–19, moderate depression 20–28, and
severe depression 29–63. The patients were examined with
a neuropsychological test battery of eight measures assessing
cognitive domains that are commonly involved in depression.
• Mini-Mental State Examination (MMSE) is a test for global
cognitive function (Folstein et al., 1975).
• Trail Making Test A (simple); Trail Making Test B
(complex): the Trail Making Test measures attention,
visual searching, mental processing speed, set shifting, and
cognitive flexibility (Strauss et al., 2006).
• Grooved Pegboard Test, a test of fine motor control: this test
measures response time in seconds with dominant and non-
dominant hand (Kløve, 1974).
• Hopkins Verbal Learning Test-R (HVLT): immediate total
recall and delayed recall (Brandt, 1991, 2001).
• Brief Visual Memory Test-R (BVMT) measures immediate
and delayed visual recall (Benedict et al., 1998).
• Wechsler Adult Intelligence Scale, 3rd Edition (WAIS-III),
the subtests of which are Digit Symbol and Symbol Search
measures processing speed, visual perception, attention and
concentration, motor and mental speed (Wechsler et al.,
2003).
• The D-KEFS Color Word Interference Test: Test 1, color
naming; Test 2, color name reading; Test 3 inhibition; Test
4 inhibition/switching. The test measures the Stroop effect,
attention, cognitive processing, and mental stimulus control
(Strauss et al., 2006).
• Controlled Oral Word Association Test (COWAT), which
measures the ability to produce words within 1 min: Words
(number of Words on F, A, and S), Clothes (number of
clothes), Animals (number of Animals named) (Strauss et al.,
2006).
Ethics Statement
The study was reviewed and approved by the Regional
Committees for Medical and Health Research Ethics, South East
A, Reference No. 2009/2196a, and all participants provided a
written informed consent form before they were included in the
study.
Statistics
Independent Mann–Whitney U-test or chi-square analyses were
performed between the two groups to test group differences in
age, education, gender, KYN, TRP, KT Ratio, depressive symptom
forms, and neuropsychological test results. Correlations among
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KYN, TRP, and KT Ratio, age, and gender were assessed
with Spearman’s rho. Linear multiple regression was used to
study independent predictors. Statistical significance was set at
p < 0.05. SPSS Version 24 (IBM Corporation, Armonk, NY,
United States) was used for the analyses.
RESULTS
Clinical examination, CSF examination, computed tomography,
or magnetic resonance imaging revealed no cerebral
neuropathology in any of the patients (The computed
tomography or magnetic resonance imaging was undertaken for
all participants in the neurological group). Controlling for age,
we analyzed our data to see if the anti-depressive drugs or the
combination of anti-depressive and anti-psychotic drugs had
had an impact on the test results in the depression group. No
significant results were found (data not shown).
Participant characteristics with comparisons between the two
study groups are shown in Table 1. There were no significant
differences with respect to TRP, KYN, or KT Ratio in serum or
CSF. When we analyzed men and women separately independent
of depression, however, women were found to have a lower
level of TRP in both serum (Mann–Whitney U-test: TRP in
serum; p = 0.001) and CSF (Mann–Whitney U-test: TRP in
CSF; p = 0.003) than men. Women also had a lower level
of KYN in serum (p = 0.029), but not CSF (p = 0.15).
No differences were found for KT Ratio (data not shown).
When the analyses were broken down for men and women
in the depression and the control group separately, the same
results were found in the depression group for TRP in serum
(p = 0.035) and CSF (p = 0.04) and for the neurological group
for TRP in serum (p = 0.018) and CSF (p = 0.006). The KYN
serum difference between women and men was not significantly
different in either the depression or control group (data not
shown).
As expected, the depression and diffuse neurological symptom
groups differed significantly on both Beck-II and MADRS.
Differences in neuropsychological performance could be seen
in Animal fluency, WAIS-III Digit symbol, The D-KEFS color
naming, Trail Making Tests A and B, and the Grooved Pegboard
non-dominant hand, with best performance in the neurological
group. There results were basically the same when controlled for
age and gender.
Table 2 presents correlations among KYN, TRP, and the KT
Ratio in serum and CSF by age and gender. KYN concentrations
in serum and CSF correlated significantly with each other; this
was not the case with TRP. Age was positively correlated with
KYN levels, but KYN in serum correlated positively with age only
for men. On the other hand, KYN in CSF correlated positively
with age, but there were no gender differences. Regarding TRP,
the correlations with age and gender were weaker, but in the
same direction as for KYN. TRP in serum was significant only
for gender, whereas TRP in CSF was related to both age and
TABLE 1 | Demographic, biological, and neuropsychological group differences in the study groups as mean (SD) or exact numbers.
Neurological group
N = 31 Mean (SD)
Depression group
N = 44 Mean (SD)
p-value, Mann–Whitney U [univariate
analysis corrected for age and gender]
Age 44.10 (13.32) 44.66 (15.06) 0.52
Gender (women/men) 22/9 23/21
Education in years 13.53 (2.36) 12.55 (2.84) 0.11
Kynurenine serum (µM) 1.99 (0.511) 2.17 (0.525) 0.06 [0.12]
Tryptophan serum (µM) 54.68 (10.80) 57.85 (12.39) 0.46 [0.73]
K/T ratio × 1000 serum 37.48 (10.74) 38.53 (10.13) 0.50 [0.23]
Kynurenine CSF (µM) 0.0616 (0.018) 0.0661 (0.027) 0.71 [0.24]
Tryptophan CSF (µM) 2.74 (2.02) 6.43 (21.60) 0.78 [0.35]
K/T ratio × 1000 CSF (µM) 27.38 (12.67) 27.34 (12.23) 0.53 [0.53]
N = 29 N = 44
Beck depression scale-II 6.5 (6.7) 30.1 (12.4) <0.001 [<0.001]
N = 19 N = 44
Montgomery Aasberg depression scale 8.1 (5.9) 28.00.(8.03) <0.001 [<0.005]
Mini-mental state examination 29.2 (1.0) 28.3 (1.8) 0.08 [0.05]
HVLT immediate total recall 23.7 (5.2) 22.6 (4.9) 0.52 [0.38]
HVLT delayed recall 9.2 (2.4) 8.3 (2.7) 0.28 [0.26]
BVMT immediate total recall 20.7 (5.4) 19.7 (7.1) 0.69 [0.56]
BVMT delayed recall 8.6 (2.3) 7.7 (2.8) 0.19 [0.11]
Trail making test A 40.4 (27.7) 51.6 (24.0) 0.011 [0.03]
Trail making test B 79.4 (32.8) 121.9 (78.6) 0.025 [0.005]
Grooved pegboard test (dominant hand) 72. 2 (15.1) 89.4 (41.1) 0.11 [0.01]
Grooved pegboard test (non-dominant hand) 80.8 (22.1) 98.0 (35.1) 0.02 [0.01]
WAIS-III digit symbol 60.3 (15.2) 51.5 (17.3) 0.046 [0.006]
WAIS-III symbol search 28.1 (8.7) 25.2 (8.3) 0.22 [0.02]
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TABLE 2 | Correlations among kynurenine, tryptophan kynurenine/tryptophan in CSF and serum correlated (rho), by age and gender.
Kynurenine
CSF (µM)
Tryptophan
CSF (µM)
Kynurenine/
Tryptophan
CSF
Kynurenine
serum (µM)
Tryptophan
serum (µM)
Kynurenine/
Tryptophan
serum
Age Gender
(women/men)
Kynurenine CSF (µM) 0.522
p < 0.001
0.496
p < 0.001
0.614
p < 0.001
−0.003
p = 0.982
0.576
p < 0.001
0.471
p < 0.001
0.168
p = 0.150
Tryptophan CSF (µM) −0.356
p = 0.002
0.162
p = 0.166
0.207
p = 0.074
−0.001
p = 0.993
0.268
p = 0.020
0.351
p = 0.002
Kynurenine/Tryptophan CSF 0.584
p < 0.001
−0.136
p = 0.244
0.650
p < 0.001
0.309
p = 0.007
−0.035
p = 0.764
Kynurenine serum (µM) 0.298
p = 0.009
0.682
p < 0.001
0.470
p < 0.001
0.254
p = 0.028
Tryptophan serum (µM) −0.423
p < 0.001
0.022
p = 0.849
0.383
p = 0.001
Kynurenine/Tryptophan serum 0.448
p < 0.001
−0.063
p = 0.592
Age 0.138
p = 0.218
Gender (women/men)
Kynurenine in serum and CSF is highly correlated with each other. Kynurenine in CSF is significantly correlated with age, but not with gender. Kynurenine in serum
is significantly correlated with age and gender. Tryptophan in serum is significantly correlated with gender but not age. Men have higher values on both kynurenine
and tryptophan in serum. Thus, only Kynurenine seems to be related to age. Only serum values of Kynurenine and Tryptophan are significantly related to gender.
Kynurenine/tryptophan in CSF and serum correlated highly with each other, and showed also positive correlations with age but not with gender.
TABLE 3 | The table shows linear regressions with the neuropsychological tests as dependent variables.
Kynurenine
serum, partial
correlations and
(p-values)
Kynurenine spinal
fluid, partial
correlations and
(p-values)
Tryptophan
serum, partial
correlation and
(p-values)
Trypophan spinal
fluid, partial
correlations and
(p-values)
KT Ratio serum,
partial
correlations and
(p-values)
KT Ratio spinal
fluid, partial
correlation and
(p-values)
BDI-II 0.07 (0.58) 0.03 (0.73) −0.008 (0.95) −0.10 (0.41) 0.08 (0.50) 0.08 (0.50)
MADRS 0.13 (0.32) 0.02 (0.88) −0.02 (0.87) −0.15 (0.38) 0.14 (0.30) 0.09 (0.50)
MMSE −0.068 (0.61) −0.29 (0.028) 0.018 (0.89) 0.06 (0.66) −0.11 (0.39) −0.16 (0.22)
HVLT learning −0.20 (0.13) −0.08 (0.57) 0.12 (0.38) 0.00 (1.00) −0.28 (0.03) −0.13 (0.33)
HVLT delayed recall −0.21 (0.16) −0.19 (0.15) 0.09 (0.52) −0.03 (0.87) −0.28 (0.03) −0.17 (0.19)
BVMT learning −0.22 (0.09) −0.12 (0.37) 0.002 (0.99) 0.00 (0.96) −0.18 (0.18) −0.09 (0.48)
BVMT delayed recall −0.21 (0.11) −0.17 (0.20) −0.05 (0.75) −0.03 (0.85) −0.14 (0.27) −0.08 (0.56)
Trail making test part A 0.11 (0.40) 0.15 (0.25) −0.25 (0.06) 0.11 (0.39) 0.30 (0.02) 0.29 (0.10)
Trail making test part B 0.06 (0.67) 0.13 (0.32) 0.04 (0.74) 0.11 (0.43) 0.11 (0.41) 0.09 (0.49)
Grooved pegboard DH 0.03 (0.85) 0.33 (0.009) −0.03 (0.54) 0.08 (0.53) 0.08 (0.55) 0.15 (0.26)
Grooved pegboard NDH 0.11 (0.41) 0.31 (0.015) −0.04 (0.79) 0.12 (0.37) 0.11 (0.42) 0.07 (0.61)
Digit symbol WAIS-III −0.09 (0.51) −0.26 (0.04) −0.11 (0.41) −0.02 (0.90) −0.17 (0.20) −0.13 (0.31)
Symbol search WAIS-III −0.08 (0.55) −0.17 (0.21) 0.15 (0.26) −0.12 (0.35) −0.16 (0.23) −0.18 (0.16)
D-KEFS color naming 0.09 (0.51) 0.26 (0.05) −0.07 (0.57) −0.03 (0.85) 0.20 (0.12) 0.27 (0.04)
D-KEFS color reading 0.07 (0.60) 0.14 (0.30) −0.04 (0.77) 0.04 (0.78) 0.13 (0.31) 0.21 (0.11)
D-KEFS inhibition −0.03 (0.83) 0.15 (0.27) −0.14 (0.28) 0.08 (0.56) 0.06 (0.65) 0.21 (0.11)
D-KEFS inhibition/switching 0.22 (0.09) 0.21 (0.10) −0.14 (0.28) −0.00 (0.98) 0.30 (0.02) 0.37 (0.004)
Verbal fluency FAS −0.17 (0.38) −0.04 (0.77) −0.02 (0.88) −0.15 (0.25) −0.14 (0.28) 0.05 (0.68)
COWA cloths −0.22 (0.10) −0.02 (0.21) −0.00 (0.99) −0.04 (0.75) −0.22 (0.10) 0.02 (0.89)
COWA animals −0.02 (0.88) 0.06 (0.68) 0.12 (0.37) −0.15 (0.27) 0.04 (0.76) 0.23 (0.07)
Independent variables: kynurenine, tryptophan, and the kynurenine/tryptophan ratio (KT Ratio). Age, gender, and group membership as covariates. Partial correlation and
(p-values) are presented.
gender. KT Ratio in CSF and serum correlated highly with each
other, and showed also positive correlations with age but not with
gender.
Table 3 presents correlations of TRP, KYN, and the KT Ratio
to predict scores on BDI-II, MADRS, and neuropsychological
tests in linear regressions, controlling for age, gender, and
group status (depression or neurological group). Because of their
distributions, Trail Making Test A and B, Grooved Pegboard Test,
and inhibition of word and color in the D-KEFS inhibition were
log transformed. No significant correlations were found between
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BDI-II/MADRS on the one hand and KYN, TRP or KT Ratio on
the other.
As can be seen in Table 3, KYN in CSF correlated with
neuropsychological performance when age, gender, and group
membership were controlled. Further associations were seen
when the KT Ratios were examined. No such correlations
were found for TRP, and no significant associations were
found between BDI-II, MADRS on the one hand and KYN,
TRP, or KT Ratio on the other. When the same tests were
performed without controlling for group status, however, the
partial correlations between KYN in CSF and KT Ratios
relative to the neuropsychological test performance were
stronger.
• KYN in CSF: MMSE, partial correlation −0.32,
p = 0.013; Grooved Pegboard dominant hand (Log
values), partial correlation = 0.34, p = 0.007; Grooved
Pegboard non-dominant hand (Log values), partial
correlation = 0.31, p = 0.017; Digit Symbol WAIS-III,
partial correlation = −0.30, p = 0.017, D-KEFS color
naming, partial correlation= 0.31, p= 0.016.
• KT Ratio in serum: HVLT-learning, partial correlation
−0.294, p = 0.022; HVLT-delayed recall, partial correlation
−0.301, p = 0.018; Log Trail Making Test Part A,
partial correlation 0.34, p = 0.008; D-KEFS color word
inhibition/switching, partial correlation= 0.32, p= 0.012.
• KT Ratio in CSF: D-KEFS color naming, partial
correlation = 0.28, p = 0.029, DKEFS inhibition/switching,
partial correlation= 0.37, p= 0.003.
DISCUSSION
We are unaware of any other study that compared a depression
group to a similar patient group, as we have done in this
study with regard to KYN, TRP, and KT Ratio in serum and
CSF.
No differences in KYN, TRP, or KT Ratio concentrations in
serum and CSF were found between the two patient groups.
Women, however, had lower levels of TRP in both serum
and CSF. Because women in general have a higher incidence
of depression, we propose that this difference may be of
importance with some parts of the development of depression.
Elovainio et al. (2012) found that the KT Ratio in serum (as
a marker of IDO) predicted depressive symptoms in women
only (p = 0.03), even after adjustment for baseline depression
scores. In a study of young adult (24–39 years) Finns, it was
found that the IDO enzyme is involved in immune regulation
of early atherosclerosis, particularly among females, and could
constitute a marker of immune activation for atherosclerosis
in females (Pertovaara et al., 2007). In examining TRP and
KYN in men and women, however, we found these markers
to be higher in men, and no gender differences were found
in KT Ratio in serum or CSF. There were relatively strong
correlations for KYN, TRP, and KT Ratio concentrations with
both age and gender (older people and men), particularly
for KYN and KT Ratio relative to age. We are aware of no
other study that has demonstrated these findings regarding
CSF in depressed patients. This finding could indicate the
involvement of other biological mechanisms as people age
(Alexopoulos, 2005). Depression in old people is often seen in
individuals with co-morbid physical disorders, which increases
the complexity of the biological mechanisms of depression
(Alexopoulos, 2005).
KYN concentrations (and KT Ratios) in serum and CSF
correlated significantly with each other. TRP in serum and CSF
showed no significant correlation. Theoretically, Interferon-γwill
enhance TRP metabolism by inducing IDO and thereby catalyze
the first step of TRP degradation, forming the KYN. Our results
could not support Interferon-γ as a specific trait in depression,
however. In addition, when we studied cytokines in serum and
CSF, as reported in another paper (Hestad et al., 2016), we found
no significant correlation between INF-γ in serum and CSF and
depression.
Although the two groups were similar with respect to
clinical symptoms, there was a clear trend toward differences
in cognitive performance between the depression and control
groups. Depression in itself, therefore, seems to be responsible
for the depression group’s inferior cognitive performance.
KYN in CSF was related to some degree to neuropsychological
performance. Poorer performance on MMSE, Grooved
Pegboard, Digit Symbol WAIS-III, and D-KEFS Color all
correlated with KYN in CSF. The partial correlations for these
tests were modest—all below 0.4. More associations were
seen with the KT Ratio, however. HVLT learning and delayed
recall and the Trail Making Test Part A were all significantly
associated with KT Ratio in serum, and this finding seems to
be partly independent of depression. Higher levels of the KT
Ratio indicated poorer performance on the neuropsychological
tests. The KT Ratio in CSF showed significant associations
with D-KEFS color naming and D-KEFS inhibiting/switching.
These findings could indicate support for the theory that too
much KYN at the expense of Serotonin results in metabolites
that influence cognitive performance (Wichers and Maes,
2004). Thus KYN in CSF and KT Ratio in both serum and
CSF may be related to some degree to cognitive performance
in the psychopathology of depression but not to affective
symptoms as measured with MADRS and BDI-II. Because
all the analyses were controlled for age, gender, and group
membership, the findings are independent of these factors.
KYN in CSF or KT Ratio may not explain all the variance
in neuropsychological performance. When the regression
analyses were performed without controlling for depression,
the associations were stronger, but in the same direction. We
therefore suggest that KYN in CSF and KT Ratio in both serum
and CSF are related to cognitive performance, as measured
by the neuropsychological tests, but not to depression, as
measured by BDI-II or MADRS. One consideration is the
effect of the variables that are being partialled out: When it
is large, the resulting statistics can be unstable, especially in
model samples. Nevertheless, without controlling for these
factors, the findings went in the same direction for the KYN,
TRP, and KT Ratios regarding depression and cognitive
performance.
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CONCLUSION
No significant differences were found between a group of
depressed patients and controls regarding KYN, TRP, KT Ratios
in serum and CSF. Women seem to have a lower level of
TRP in both serum and CSF than men do. There was a clear
trend toward inferior neuropsychological performance in the
depression group compared to the controls. KYN, TRP, and
KT Ratio are strongly related to age and gender in the two
samples, independent of depression. In the original studies
of KYN and TRP related to medication with Interferon-α,
the vegetative or sickness symptoms emerged weeks before
depression (Capuron et al., 2002a,c, 2004). The symptoms
pointed out are malaise, lassitude, fatigue, numbness, coldness,
muscle and joint aches, and reduced appetite. Thus, KYN
and KT Ratio could be related more strongly to sickness
than to affective symptoms, manifested in our study as poorer
neuropsychological performance. The cognitive symptoms were
related to KYN in CSF and KT Ratio in both serum and CSF.
This was not so for the affective symptoms, which seem to be
independent of both TRP and KYN. Low-grade inflammation
related to KYN and TRP with the pathway of IDO in serum
or plasma has been shown to be related to depression. It may
be that this relationship relates in turn not to the affective
symptoms, but to cognitive impairment. We suggest that a
rise in inflammatory markers in depression is an indicator
of general malfunction and that anti-depressive drugs, ECT,
and physical activity may help alleviate these symptoms. It is
suggested that the mechanism behind it is through treatment
of activated inflammation, and that there is a close connection
between body and mind. Treat the body, and it will be easier
to treat the mind—the depressive symptoms. We believe that
it will be necessary to study the interaction between body
and mind in the treatment of depression and other similar
disorders such as tiredness and fatigue. For the future it would
be interesting to examine whether KYN, TRP and the ratio of
KT are correlated with other variables in depression, such as
treatment resistance, depression duration, number of episodes,
and not least, sickness behavior, with such factors as malaise,
lassitude, fatigue, numbness, muscle and joint aches, and changes
in appetite.
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